

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM397019

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
GLAXOSMITHKLINE BIOLOGICALS S.A.		10/30/2015	Corporation: BELGIUM
RECEIVING PARTY DATA			
Name:	VALNEVA AUSTRIA GMBH		
Street Address:	Campus Vienna Biocenter 3		
City:	Vienna		
State/Country:	AUSTRIA		
Postal Code:	1030		
Entity Type:	Corporation: AUSTRIA		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	2775583	IXIARO	
Registration Number:	3168727	IXIARO	
Registration Number:	3660894	IXIARO	
CORRESPONDENCE DATA			
Fax Number:	2129499190		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	(212) 949-9022		
Email:	VMTannenbaum@lawabel.com		
Correspondent Name:	Victor Tannenbaum		
Address Line 1:	666 Third Avenue		
Address Line 2:	10th Floor		
Address Line 4:	New York, NEW YORK 10017		
NAME OF SUBMITTER:	Victor Tannenbaum		
SIGNATURE:	/VMT/		
DATE SIGNED:	08/31/2016		
Total Attachments: 33			
source=IXIARO US POA#page1.tif			
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page1.tif			

OP \$90.00 2775583

source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page2.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page3.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page4.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page5.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page6.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page7.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page8.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page9.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page10.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page11.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page12.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page13.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page14.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page15.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page16.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page17.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page18.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page19.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page20.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page21.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page22.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page23.tif
source=Valneva Austria-GlaxoSmithKline Deed of Assignment#page24.tif
source=Records - 2775583#page1.tif
source=Records - 2775583#page2.tif
source=Records - 2775583#page3.tif
source=Records - 2775583#page4.tif
source=Records - 3660894#page1.tif
source=Records - 3660894#page2.tif
source=Records - 3168727#page1.tif
source=Records - 3168727#page2.tif

UNITED STATES

REVOCAATION

AND

NEW POWER OF ATTORNEY

Mark: IXIARO, IXIARO and device

Registration: 2775583,3168727,
3660894, 992889

Serial No.: TRM032/TRM033

Classes: 5

Owner: Valneva Austria GmbH

APPOINTMENT OF DOMESTIC REPRESENTATIVE

Abelman, Frayne & Schwab, whose postal address is 666 Third Avenue, New York, New York 10017-5621, U.S.A. is hereby designated applicant's representative upon whom notices or process in proceedings affecting the mark may be served.

POWER OF ATTORNEY

Applicant hereby revokes all previous Powers of Attorney and hereby appoints jointly and severally, with full power of substitution, the power of appointment of an associate attorney and the power of revocation


Lawrence E. Abelman
Jeffrey A. Schwab
Victor M. Tannenbaum
Peter J. Lynfield
Caridad Piteiro Scordato

Julianne Abelman
Thomas E. Spath
Julie B. Seyler
Marie-Anne Mastrovito
Frank Terranella

members of the Bar of the State of New York, whose address is

ABELMAN, FRAYNE & SCHWAB
666 Third Avenue
New York, New York 10017-5621, U.S.A.

to transact business in the Patent and Trademark Office in connection with our trademarks, applications therefor, and registrations which have or will issue thereon.


By Adrian Spillmann, PhD, LL.M.,
Corporate Head of IP
Date April 7, 2016

EXECUTION VERSION

Dated 30 October 2016

Valneva Austria GmbH

And

GlaxoSmithKline Biologicals SA
and

GlaxoSmithKline GmbH and Co. KG

TRADEMARK AND DOMAIN NAME ASSIGNMENT AGREEMENT

EXECUTION VERSION

THIS ASSIGNMENT is made the 30 of October 2015 (the "Effective Date")

BETWEEN:

- (1) GLAXOSMITHKLINE BIOLOGICALS SA, a company incorporated under the laws of Belgium, with its principal place of business at 89, rue de l'Institut, 1330 Rixensart, Belgium, registered with the Legal Entity Register (RPM Nivelles) under number 0440.872.918; and
- (2) GLAXOSMITHKLINE GMBH AND CO, KG, a company duly incorporated under the laws of Germany with company registration number HRA 78754 and whose registered office is at Prinzregentenplatz 8, 81876, Munich, Germany;

(collectively being the "Assignors");

- (3) VALNEVA AUSTRIA GMBH, a company incorporated under the laws of Austria, with its principal place of business at Campus Vienna BioCenter 3, 1030 Vienna, Austria, registered with the Register of Companies (Firmenbuch) under number 389960x (hereinafter referred to as "Valneva").

(the "Assignee").

(each, a "Party" and together, the "Parties").

WHEREAS:-

- (A) This Assignment is entered into pursuant to the Agreement on the Transfer of IXIARO Business entered into on or about the same date as this Assignment (the "Agreement on the Transfer").
- (B) The Assignors are the proprietors of the trade marks listed in Schedule 1 hereto (the "Trade Marks") and the domain names listed in Schedule 2 hereto (the "Domain Names"). The Trade Marks and Domain Names have been acquired by the Assignors from Novartis on 2 March 2015 and most of the records of assignment before the relevant Authorities from Novartis to the Assignors (the "Records of Prior Assignment") have been requested and are either pending or completed.
- (C) The Assignors have agreed in the Agreement on the Transfer to assign, or procure the assignment of, the Trade Marks and the Domain Names to the Assignee.

NOW IT IS HEREBY AGREED as follows:

1. ASSIGNMENT

- 1.1 In consideration of the payments made under the Agreement on the Transfer, the Assignors hereby assigns to the Assignee all its right, title and interest in and to the Trade Marks together with all goodwill of the business in relation to which such Trade Marks are used (but no other or greater goodwill), including all rights, privileges and

advantages thereto, including, without limitation, the right to take proceedings and recover damages and obtain all other remedies in respect of past infringements thereof, to hold unto the Assignee absolutely for the full term of the Trade Marks. The Assignee hereby agrees to such assignment upon the terms and conditions stated herein.

- 1.2 In consideration of the payments made under the Agreement on the Transfer, each of the Assignors hereby assigns to the Assignee all its right, title and interest in and to the Domain Names set out in Schedule 2, together with all rights, privileges and advantages thereof, to hold unto the Assignee absolutely for the full term of the Domain Names. The Assignee hereby agrees to such assignment upon the terms and conditions stated herein.
- 1.3 The Assignee grants the Assignors a world-wide non-exclusive royalty free licence to use the Trade Marks and Domain Names for as long as it is required for the Assignors to fulfill their obligations under the Agreement on the Transfer.
- 1.4 The Assignee will take over representation before the relevant Trade Mark Offices for all ongoing trade mark conflicts within 2 months from the Effective Date.


2. NO WARRANTIES


The Assignors do not give, and the Assignee acknowledges that neither the Assignors nor any other person have given, any representation, warranty or assurance of any nature, express or implied, in respect of any of the Trade Marks or the Domain Names, except for a warranty that to the best of the Assignors' trademark counsel's knowledge as of the date of this Agreement, a) the Assignors own all rights, title and interest in and to the Trade Marks and the Domain Names, b) all the applicable trademark fees owed to the relevant trademark offices to date have been paid in full and c) the Trade Marks are free from any pledge, lien, encumbrance, security interest and third party rights. It shall not be a breach of this warranty if the Assignors, after signing this Agreement, become aware of circumstances which arose before 2 March 2015 in cases where such circumstances would constitute a breach of this warranty had they arisen after 2 March 2015.

3. FURTHER ASSURANCE


Without prejudice to any restriction or limitation on the extent of any Party's obligations under this Agreement, at the cost of the Assignee, each of the Parties shall from time to time, so far as each is reasonably able, do or procure the doing of all such acts and/or execute or procure the execution of all such documents as are reasonably necessary to effectuate the transfer of the Trade Marks and the Domain Names to the Assignee pursuant to this Agreement or otherwise to give any other Party the full benefit of its rights under this Agreement. The Assignors shall at their expense (a) complete all Records of Prior Assignment, (b) file the same with all appropriate authorities, (c) notify the Assignee upon such completion and filing in each country and (d) remove all links to any Novartis websites from the Domain Names.

IN WITNESS WHEREOF the Assignment has been executed by or on behalf of the parties on the date first above written


Andron Loernans
SVP GC


PPA


Tom Whitman



FRANCK GRIMAUD


THOMAS LINGELBACH

SCHEDULE 1
TRADE MARKS

Country	Registration Status	Registration No.	Registration Date	Priority No.	Priority Date	Class	Description	Applicant	Remarks
Albania	Registered	784141	19/Apr/2010	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.	
Algeria	Registered	784141	31/Oct/2008	784141	23/Jul/2002	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	
Argentina	Registered	3238894	19/Apr/2013	2865478	16/Jun/2014	5	Pharmaceutical preparations.	GlaxoSmithKline Biologicals S.A.	X
Australia	Registered	784141	23/Jul/2003	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.	
Bahamas	Application	32423	15/Jan/2009			3	vaccines for human use; and all other goods included in Class 3.	GlaxoSmithKline Biologicals S.A.	X
Bangladesh	Application	C17834	14/Jan/2013			5	Vaccines for human use.	Novartis AG	
Belarus	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.	
Bermuda	Registered	48782	09/Jun/2009	48782	15/Oct/2008	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X
BGO Islands (Bonaire, Sint Eustatius and Saba)	Registered	784141	31/Oct/2008	784141	23/Jul/2002	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	
Bolivia	Registered	3MGS3806	29/Oct/2008	120196C	23/Sep/2008	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X
Bosnia and Herzegovina	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.	
Brazil	Application	024723680	05/Aug/2002			5	Pharmaceutical preparations.	GlaxoSmithKline Biologicals S.A.	X
British Virgin Islands	Registered	3710	29/Jan/2009	5017	16/Aug/2008	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X

WIARO	Guatemala	Registered	47782002	17/Jul/2002	120487	24/Oct/2003	USA	Pharmaceutical preparations for the prevention and/or treatment of disorders of the nervous system, the immune system, the cardiovascular system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, in oncology, in ophthalmology, for use in the gastrointestinal tract and the prevention and treatment of ocular disorders or diseases	GlaxoSmithKline Biologicals S.A.	X
WIARO	Honduras	Registered	01952002	15/Jul/2002	85244	27/May/2003	USA	Pharmaceutical preparations	GlaxoSmithKline Biologicals S.A.	
WIARO	Hong Kong	Registered	107362002	13/Jul/2002	3753200	18/Aug/2003	USA	Pharmaceutical preparations for the	GlaxoSmithKline Biologicals S.A.	X

							prevention and/or treatment of disorders of the nervous system, the immune system, the cardiovascular system, the respiratory system, the musculoskeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, in oncology, in ophthalmology, for use in the gastrointestinal area and the prevention and treatment of cardiovascular diseases.			
WARG	Iceland	Registered	784141	23/Jun/2002	784141	23/Jun/2002	5	GlaxoSmithKline Biologicals S.A.		
WARG	India	Registered	1118963	16/Jun/2002	1118963	16/Jun/2002	5	Pharmaceutical preparations.	GlaxoSmithKline Biologicals S.A.	X
WARG	Indonesia	Registered	0002009030320	07/Jun/2009	DM030281148	21/Jun/2010	15	Vaccine for human use.	GlaxoSmithKline Biologicals S.A.	X
WARG	Israel	Registered	168164	11/Jun/2002	168164	05/Aug/2003	15	Pharmaceutical preparations for	GlaxoSmithKline Biologicals S.A.	

							the nervous system, the treatment of disorders of the nervous system, the immune system, the cardiovascular system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, in oncology, in ophthalmology, for use in the gastrointestinal area and the prevention and treatment of ocular disorders or diseases.		
MARKO	Japan	Registered	784141	23/Jun/2002	784141	23/Jun/2002	5	GlenoSmithKline Biologicals S.A.	
MARKO	Jordan	Registered	104388	28/Dec/2008	104388	12/Sep/2008	5	Vaccines for human use.	X
MARKO	Kazakhstan	Registered	80783	21/Jan/2013	83462	23/Feb/2013	5	Vaccines for human use.	X
MARKO	Kosovo	Registered	RR794141	23/Jun/2002	7834	31/Mar/2011	5	Pharmaceutical preparations	

IXIARO	Kuwait	Registered	100315	26/Dec/2008	80953	07/Feb/2010	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	
IXIARO	Lebanon	Registered		13/Jan/2008	120883	13/Jan/2008	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X
IXIARO	Liechtenstein	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.	
IXIARO	Macedonia	Registered	784141	31/Dec/2008	784141	23/Jul/2002	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	
IXIARO	Malaysia	Registered	08026318	26/Dec/2008	8025318	26/Dec/2008	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X
IXIARO	Mexico	Registered	1011042	06/Jun/2009	1142122	10/Feb/2010	5	Pharmaceutical preparations.	GlaxoSmithKline Biologicals S.A.	X
IXIARO	Moldova	Registered	784141	03/Jan/2013	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.	
IXIARO	Monaco	Registered	784141	31/Dec/2008	784141	23/Jul/2002	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	
IXIARO	Montenegro (Republic of)	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.	
IXIARO	Morocco	Registered	784141	31/Dec/2008	784141	23/Jul/2002	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	
IXIARO	Namibia	Application	20130228	28/Feb/2013			5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	
IXIARO	New Zealand	Registered	600753	15/Jul/2002	600753	15/Jul/2002	5	Pharmaceutical preparations.	GlaxoSmithKline Biologicals S.A.	
IXIARO	Nicaragua	Registered	20021915	17/Jul/2002	66798	04/Feb/2003	5	Pharmaceutical preparations for the prevention and/or treatment of disorders of the nervous system, the immune system, the cardiovascular system.	Novartis AG.	

							the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, in oncology, in ophthalmology, for use in the gastrointestinal area and the prevention and treatment of ocular disorders of horses.			
DIARO	Nigeria	Registered	FTMO20132032	18/Jan/2013	1898306 1704010 40	18/Jan/2013	5	Vaccines for human use	Novartis AG.	
DIARO	Norway	Registered	299703463	23/Mar/2007	240262	18/Dec/2007	5	Pharmaceutical preparations.	GlaxoSmithKline Biologicals S.A.	
DIARO	Norway	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.	
DIARO	GAPI (African Union)	Registered	920390060	18/Jan/2009	81353	31/Dec/2009	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X
DIARO	Oman	Registered	784141	31/Dec/2006	784141	23/Jul/2002	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	
DIARO	Pakistan	Registered	179105	15/Jul/2002	179105	15/Jul/2002	5	Pharmaceutical preparations for the prevention and/or treatment of disorders of the	GlaxoSmithKline Biologicals S.A.	X

								nervous system, the immune system, the nervous system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory reactions, for use in dermatology, in oncology, in ophthalmology, for use in the gastrointestinal area and the prevention and treatment of ocular infections or diseases, being goods in Int. Class 05.		
IXIARO	Panama	Registered	178340	06/Jun/2009	178340	15/Sep/2009	5	Vaccines for human use	GlaxoSmithKline Biologics S.A.	
IXIARO	Paraguay	Registered	18820	12/Jun/2007	268614	26/Jun/2008	5	Pharmaceutical preparations	Novartis AG	
IXIARO	Peru	Registered	168864	12/Jun/2007	80808	09/Jul/2009	5	Pharmaceutical preparations	GlaxoSmithKline Biologics S.A.	X
IXIARO	Philippines	Registered	42012005318	02/May/2012	42012006318	23/Aug/2012	05	Vaccines for human use	GlaxoSmithKline Biologics S.A.	X

IXIARO	Poland	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.
IXIARO	Russian Federation	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.
IXIARO	San Marino	Registered	784141	31/Dec/2000	784141	23/Jul/2002	5	vaccines for human use.	GlaxoSmithKline Biologicals S.A.
IXIARO	Saudi Arabia	Registered	188287	27/Dec/2008	114888	17/Mar/2013	5	Vaccines for human use.	Novartis AG
IXIARO	Serbia (Republic of)	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.
IXIARO	Singapore	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.
IXIARO	Sint Maarten (NL part of Sint Maarten)	Registered	784141	31/Dec/2008	784141	23/Jul/2002	5	vaccines for human use.	GlaxoSmithKline Biologicals S.A.
IXIARO	Slovak Republic	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.
IXIARO	Slovenia	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.
IXIARO	South Africa	Registered	200210122	12/Jul/2002	200210122	30/Jun/2005	5	Pharmaceutical preparations.	GlaxoSmithKline Biologicals S.A.
IXIARO	South Korea (Republic of)	Registered	200202198	12/Jul/2002	665194	12/Nov/2003	5	Pharmaceutical preparations for the prevention and/or treatment of disorders of the nervous system, the immune system, the cardiovascular system, the respiratory system, the musculoskeletal system, the genitourinary system, for the	GlaxoSmithKline Biologicals S.A.

								treatment of inflammatory disorders for use in dermatology, oncology, in ophthalmology, for use in the gastroenterological area and the prevention and treatment of ocular disorders or diseases.		
WIPO	Sri Lanka	Application	148986	07/Jan/2008			5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X
WIPO	Switzerland	Registered	081242002	11/Jul/2002	561311	23/Mar/2007	5	Pharmaceutical preparations.	Novartis AG	
WIPO	Taiwan	Registered	81030045	12/Jul/2002	1648550	01/Jul/2003	5	Pharmaceutical preparations.	GlaxoSmithKline Biologicals S.A.	
WIPO	Thailand	Registered	482498	15/Jul/2002	16417603	17/Apr/2003	6	Pharmaceutical preparations for the prevention and/or treatment of disorders of the nervous system, the immune system, the cardiovascular system, the respiratory system, the musculoskeletal system, the genitourinary	GlaxoSmithKline Biologicals S.A.	X

											system, for the treatment of inflammatory disorders, for use in dermatology, in oncology, in ophthalmology, for use in the gastrointestinal area and the prevention and treatment of ocular disorders or diseases.		
DIARO	Trinidad and Tobago	Registered	40699	30/Dec/2008	40699	13/Jul/2009	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.			X	
DIARO	Tanzania	Registered	EE083078	25/Dec/2008	EE083078	30/Mar/2010	6	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.				
DIARO	Turkey	Registered	784141	23/Jul/2002	784141	22/Jul/2002	5		GlaxoSmithKline Biologicals S.A.				
DIARO	Turks and Caicos Islands	Registered	16780	29/Jan/2009	16780	18/Mar/2009	6	Vaccines for human use.	Novartis AG				
DIARO	Ukraine	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5		GlaxoSmithKline Biologicals S.A.				
DIARO	United Arab Emirates	Registered	125173	30/Dec/2008	168188	16/May/2010	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.			X	
DIARO	Uruguay	Registered	398934	30/Dec/2008	398934	14/Sep/2010	6	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.			X	
DIARO	USA	Registered	77801317	02/Feb/2009	3660884	28/Aug/2009	6	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.				
DIARO	USA	Registered	78144187	18/Jul/2002	2776983	21/Jul/2005	5	Pharmaceutical preparations for the prevention and treatment of disorders.	GlaxoSmithKline Biologicals S.A.				

							of the nervous system, * namely, *epinephrine, *acetylcholine, *the immune system, the cardio-vascular system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of infectious diseases, for use in dermatology, in oncology, in ophthalmology, for use in the genitourinary area and for prevention and treatment of ocular diseases; anti-infectives (antibacterials, antivirals, antifungals, anti-parasitics)	
IXARO	USA	Registered	78788170	24/jan/2008	3188727	07/may/2008	Pharmaceutical preparations for the treatment	GlaxoSmithKline Biologicals S.A.

							of and/or prevention of disorders of the nervous system, the immune system, the cardiovascular system including diabetes and metabolic diseases, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, its use in dermatology, its use in oncology, its use in hematology, its use in transplantation, its use in ophthalmology, its use in the gastrointestinal tract, its use in the treatment of renal disorders or diseases; pharmaceutical preparations including but not limited to		
--	--	--	--	--	--	--	---	--	--

							diseases; ant- adhesives; ant- bacterials; antivirals; ant- biotics; ant- fungal;] vaccines;]; diagnosti- c preparati- ons for medical use			
IXIARO	Uzbekistan	Registered	784141	03/Jan/2013	784141	23/Jul/2002	5	GlaxoSmithKline Biologicals S.A.		
IXIARO	Venezuela	Registered	2008024864	29/Dec/2008	P300787	17/Nov/2009	5	Vaccines for human use	Novartis AG	
IXIARO	Vietnam	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5	GlaxoSmithKline Biologicals S.A.		
IXIARO	WIPO	Registered	784141	23/Jul/2002	784141	23/Jul/2002	5	Pharmac- euti- cal preparati- ons	GlaxoSmithKline Biologicals S.A.	
IXIARO	Zimbabwe	Registered	32009	07/Jan/2009	32009	21/Mar/2011	5	Vaccines for human use	GlaxoSmithKline Biologicals S.A.	X

IXIARO AND DEVICE

IXIARO

IXIARO AND DEVICE	Argentina	Registered	0967072	17/Dec/2008	0324001	29/Oct/2009	5	Vaccines for human use	GlaxoSmithKline Biologicals S.A.	X
IXIARO AND DEVICE	Australia	Registered	902689	29/Dec/2008	902688	29/Dec/2008	5		GlaxoSmithKline Biologicals S.A.	
IXIARO AND DEVICE	Belarus	Registered	902689	29/Dec/2008	902688	29/Dec/2008	5		GlaxoSmithKline Biologicals S.A.	
IXIARO AND	Bosnia and Herzegovina	Registered	902689	29/Dec/2008	902689	29/Dec/2008	5		GlaxoSmithKline Biologicals S.A.	

MARK AND DEVICE	Country	Registered	Application No.	Priority Date	Registration No.	Registration Date	Class	Description	Applicant	Priority
MARK AND DEVICE	Brazil	Registered	801750229	16/Oct/2008	801266829	19/Apr/2011	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X
MARK AND DEVICE	Canada	Registered	1414055	17/Oct/2008	11MA75809	27/Jun/2010	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	
MARK AND DEVICE	Chile	Registered	841195	16/Oct/2008	853519	24/Jun/2009	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X
MARK AND DEVICE	China (Peoples Republic)	Registered	992889	29/Dec/2008	992888	23/Oct/2008	5		GlaxoSmithKline Biologicals S.A.	
MARK AND DEVICE	Colombia	Registered	8110942	17/Oct/2008	882542	30/Jun/2009	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	
MARK AND DEVICE	Costa Rica	Registered	230810473	22/Oct/2008	180152	11/May/2009	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	
MARK AND DEVICE	Cuba	Registered	932889	29/Dec/2008	932889	29/Dec/2008	5		GlaxoSmithKline Biologicals S.A.	
MARK AND DEVICE	Ecuador	Registered	226337	16/Oct/2008	237355	13/Mar/2009	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X
MARK AND DEVICE	Egypt	Registered	992889	29/Dec/2008	992889	29/Dec/2008	5		GlaxoSmithKline Biologicals S.A.	
MARK AND DEVICE	EU	Registered	007328038	29/Oct/2008	007328038	09/Jun/2010	5	Vaccines for human use	GlaxoSmithKline Biologicals S.A.	
MARK AND DEVICE	Guatemala	Registered	14083042004	22/Oct/2008	164082	26/Jun/2009	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X
MARK AND	Honduras	Registered	3528828	22/Oct/2008	113124	19/Jul/2010	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	

DEVICE											
DIARO AND DEVICE	Hong Kong	Registered	331222983	17/Oct/20 08	301222983	29/Feb/2 08	5	Vaccines for human use.,	GlaxoSmithKline Biologics S.A.	X	
DIARO AND DEVICE	Iceland	Registered	992889	29/Dec/2 08	992889	29/Dec/2 08	5		GlaxoSmithKline Biologics S.A.		
DIARO AND DEVICE	India	Registered	1748289	20/Oct/20 08	823891	07/Feb/2 011	5	Vaccines for human use.,	GlaxoSmithKline Biologics S.A.	X	
DIARO AND DEVICE	Israel	Registered	215618	19/Oct/20 08	215618	11/May/2 010	5	Vaccines for human use.,	GlaxoSmithKline Biologics S.A.		
DIARO AND DEVICE	Japan	Registered	982889	29/Dec/2 08	982889	29/Dec/2 08	5		GlaxoSmithKline Biologics S.A.		
DIARO AND DEVICE	Liechtenstein	Registered	982889	29/Dec/2 08	982889	29/Dec/2 08	5		GlaxoSmithKline Biologics S.A.		
DIARO AND DEVICE	Mexico	Registered	988746	30/Oct/20 08	1079679	19/Jun/20 08	5	Vaccines for human use.,	GlaxoSmithKline Biologics S.A.	X	
DIARO AND DEVICE	Montenegro (Republic of)	Registered	982889	29/Dec/2 08	982889	29/Dec/2 08	5		GlaxoSmithKline Biologics S.A.		
DIARO AND DEVICE	New Zealand	Registered	787788	17/Oct/20 08	787788	23/Apr/20 07	5	Vaccines for human use.,	GlaxoSmithKline Biologics S.A.		
DIARO AND DEVICE	Nicaragua	Registered	200803818	23/Oct/20 08	201803818 4LM	04/Mar/2 010	5	Vaccines for human use.,	Novartis AG		
DIARO AND DEVICE	Norway	Registered	982889	29/Dec/2 08	982889	29/Dec/2 08	5		GlaxoSmithKline Biologics S.A.		
DIARO AND DEVICE	Pakistan	Registered	257006	20/Oct/20 08	257006	31/Jan/20 13	5	Vaccines for human use.,	GlaxoSmithKline Biologics S.A.	X	

DEVICE											
IXIARO AND DEVICE	Paraguay	Registered	8040292	24/Oct/2008	334702	30/Jun/2010	5	Vaccines for human use.	Novartis AG.		
IXIARO AND DEVICE	Peru	Registered	071333	23/Oct/2008	152832	20/May/2009	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.	X	
IXIARO AND DEVICE	Russian Federation	Registered	992889	29/Dec/2008	992889	29/Dec/2008	5		GlaxoSmithKline Biologicals S.A.		
IXIARO AND DEVICE	Serbia (Republic of)	Registered	992889	29/Dec/2008	992889	29/Dec/2008	5		GlaxoSmithKline Biologicals S.A.		
IXIARO AND DEVICE	Singapore	Registered	992889	29/Dec/2008	992889	29/Dec/2008	5		GlaxoSmithKline Biologicals S.A.		
IXIARO AND DEVICE	South Africa	Registered	200824640	17/Oct/2008	200824670	16/Nov/2010	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.		
IXIARO AND DEVICE	South Korea (Republic of)	Registered	4020080049734	20/Oct/2008	400806583	06/Nov/2008	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.		
IXIARO AND DEVICE	Switzerland	Registered	993672008	12/Aug/2008	975801	20/Aug/2008	0	Vaccines for human use.	Novartis AG		
IXIARO AND DEVICE	Taiwan	Registered	97040318	28/Oct/2008	1307518	01/Jul/2009	5	Vaccines for human use.	GlaxoSmithKline Biologicals S.A.		
IXIARO AND DEVICE	Thailand	Registered	712142	21/Oct/2008	110214317	30/Apr/2010	5	Japanese encephalitis vaccines.	GlaxoSmithKline Biologicals S.A.	X	
IXIARO AND DEVICE	Turkey	Registered	992889	29/Dec/2008	992889	29/Dec/2008	5		GlaxoSmithKline Biologicals S.A.		
IXIARO AND	Ukraine	Registered	992889	29/Dec/2008	992889	29/Dec/2008	5		GlaxoSmithKline Biologicals S.A.		

DEVICE										
DIARD AND DEVICE	USA	Registered	982889	29/Dec/2008	982889	29/Dec/2008	5			GlaxoSmithKline Biologicals S.A.
DIARD AND DEVICE	Vietnam	Registered	982888	29/Dec/2008	982888	29/Dec/2008	5			GlaxoSmithKline Biologicals S.A.
DIARD AND DEVICE	WIPO	Registered	982890	29/Dec/2008	982890	29/Dec/2008	6	Vaccines for human use.		GlaxoSmithKline Biologicals S.A.

DIARD in traditional chinese (fii ruc)

疫利諾

DIARD in traditional chinese (fii ruc)	Taiwan	Registered	101004181	31/Jan/2012	0154985	01/Dec/2012 <th>5</th> <th>Vaccines for human use.</th> <th></th> <th>GlaxoSmithKline Biologicals S.A.</th>	5	Vaccines for human use.		GlaxoSmithKline Biologicals S.A.

DIARD in traditional chinese (f sha lu)



易夏樂

DIARD in traditional chinese (f sha lu)	Taiwan	Registered	101004155	31/Jan/2012	0154986	01/Dec/2012 <th>5</th> <th>Vaccines for human use.</th> <th></th> <th>GlaxoSmithKline Biologicals S.A.</th>	5	Vaccines for human use.		GlaxoSmithKline Biologicals S.A.
DIARD in traditional chinese (f sha lu)	Taiwan	Registered	101004160	31/Jan/2012	0154987	01/Dec/2012	5	Vaccines for human use.		GlaxoSmithKline Biologicals S.A.


SCHEDULE 2
DOMAIN NAMES

Domain name	Owner	Registration date
kiaro.ch	GlaxoSmithKline Biologicals S.A.	05/08/2009
kiaro.com	GlaxoSmithKline Biologicals S.A.	09/07/2002
kiaro.de	GlaxoSmithKline GmbH and Co. KG	16/08/2008
kiaro.eu	GlaxoSmithKline Biologicals S.A.	16/08/2008
kiaro.info	GlaxoSmithKline Biologicals S.A.	09/07/2002
kiarohelathedydeploy.com	GlaxoSmithKline Biologicals S.A.	24/08/2009
kiarodefense.com	GlaxoSmithKline Biologicals S.A.	24/08/2009
encephalitelaponaise.ch	GlaxoSmithKline Biologicals S.A.	21/04/2010
encephalite-japonaise.ch	GlaxoSmithKline Biologicals S.A.	21/04/2010
japanischeenzephalitis.ch	GlaxoSmithKline Biologicals S.A.	05/08/2009
japanische-enzephalitis.ch	GlaxoSmithKline Biologicals S.A.	05/08/2009



Signed by
for and on behalf of
Valneva Austria GmbH


THOMAS LINGELBACH

FRANK GRÖBNER

Signed by
for and on behalf of
GlaxoSmithKline Biologicals
SA


Anton Komar
SVP, SA

Signed by
for and on behalf of
GlaxoSmithKline GmbH and
Co. KG


ppa 

INTELLECTUAL PROPERTY LAW

Client Reference : 456

Date Generated : July 25, 2016

CURRENT RECORD

US Federal

IXIARO

Status: Renewed

Affidavit(s): 8 ACCEPTED

Last Status Received: Renewed, October 21, 2013

Most Recent Owner:

Glaxosmithkline Biologicals S.A. (Belgium Corp.)

Goods/Services:

Int'l Class(es): 5 (U.S. Class: 6, 18, 44, 46, 51, 52)

Pharmaceutical preparations for the prevention [and treatment] of disorders of the nervous system, *, namely, [japanese encephalitis vaccines * [the immune system, the cardio-vascular system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, in oncology, in ophthalmology, for use in the gastroenterological area and the prevention and treatment of ocular disorders or diseases; anti-infectives, antibacterials, antivirals, antibiotics, anti-fungals]

APPLICATION / REGISTRATION INFO.

Registration No.: 2775583

Registered: October 21, 2003

Serial No.: 78-144167

Filed: July 16, 2002

Published: July 29, 2003

Trademark Type: Word

Last Renewal: October 21, 2013

Publications:

2003-31

Section: Publication Date of Application

Published: July 29, 2003

Type: Section 44(E) Claimed

Priority:

Country: Switzerland

Priority No: 6124/2002

Priority Date: July 11, 2002

Comment: Section 44(D) Priority Claimed

Register Type: Principal Register

ADDITIONAL INFO.

Correspondence Address:

ANGELA L. WILSON GLAXOSMITHKLINE
LEGAL GLOBAL TRADEMARKS, MAILSTOP: 5.5A FIVE MOORE
DRIVE; RESEARCH TRIANGLE PARK NC 27709-0183

History:

Effective Date: October 21, 2013

International Information

Foreign Designations:

Foreign: Switzerland

Application No.: 6124/2002

Registration No.: 501311

Section 44(D) Priority Claimed.

Filed: July 11, 2002

Registered: November 28, 2002

Expiration: November 28, 2012

Events:

August 26, 2015 - ASSIGNMENT OF OWNERSHIP NOT UPDATED
AUTOMATICALLY
July 22, 2015 - AUTOMATIC UPDATE OF ASSIGNMENT OF
OWNERSHIP
June 8, 2015 - TEAS Change of Correspondence Received
June 3, 2015 - AUTOMATIC UPDATE OF ASSIGNMENT OF
OWNERSHIP
June 2, 2015 - Attorney Revoked And/Or Appointed
June 2, 2015 - TEAS Revoke/Appoint Attorney Received
September 19, 2013 - NOTICE OF ACCEPTANCE OF SEC. 8 & 9 -
MAILED
September 19, 2013 - REGISTERED AND RENEWED (FIRST
RENEWAL - 10 YRS)
September 19, 2013 - Registered - Sec. 8 (10-Yr) Accepted/Sec. 9
Granted
September 11, 2013 - Registered - Combined Section 8 (10-Yr) &
Sec. 9 Filed
September 19, 2013 - CASE ASSIGNED TO POST REGISTRATION
PARALEGAL
September 11, 2013 - TEAS Section 8 & 9 Received
November 18, 2009 - Amendment Under Section 7 - Issued
November 18, 2009 - CASE ASSIGNED TO POST REGISTRATION
PARALEGAL
October 13, 2009 - TEAS SECTION 7 REQUEST RECEIVED
October 1, 2009 - Registered - Sec. 8 (6-Yr) Accepted
October 1, 2009 - CASE ASSIGNED TO POST REGISTRATION
PARALEGAL
September 15, 2009 - TEAS Section 8 Received
July 28, 2008 - Case File in TICRS
January 2, 2008 - Attorney Revoked And/Or Appointed
January 2, 2008 - TEAS Revoke/Appoint Attorney Received
December 19, 2004 - TEAS Change of Correspondence Received
December 6, 2004 - Paper Received
September 8, 2003 - Paper Received
October 21, 2003 - Registered-Principal Register
July 29, 2003 - Published For Opposition
July 9, 2003 - Notice of Publication
June 30, 2003 - TEAS Change of Correspondence Received
May 16, 2003 - Approved for Pub - Principal Register
April 17, 2003 - Correspondence Received in law office
April 21, 2003 - Sec. 1(B) Claim Deleted
April 21, 2003 - Correspondence Received in law office
April 21, 2003 - Paper Received
November 17, 2002 - Non-Final Action E-Mailed
November 14, 2002 - Assigned to Examiner
Intent to use: FILED AS INTENT TO USE
TradeMark status details: RENEWED
AM: AMENDED DECEMBER 22, 2009 - GOODS/SERVICES

OWNER INFORMATION

2nd New Owner After Registration:

GLAXOSMITHKLINE BIOLOGICALS S.A. (BELGIUM CORP.)
RUE DE L' INSTITUT 89 RIXENSART, B-1330
Belgium

1st New Owner After Registration:

GLAXOSMITHKLINE BIOLOGICALS S.A. (BELGIUM CORP.)
RUE DE L'INSTITUT 89 1330 RIXENSART
Belgium

Registrant:

NOVARTIS AG (SWITZERLAND CORP.)
CH-4002 BASEL
Switzerland

Owner At Publication:

NOVARTIS AG (SWITZERLAND CORP.)
CH-4056 BASEL
Switzerland

Applicant:

NOVARTIS AG (SWITZERLAND CORP.)
CH-4056 BASEL
Switzerland

ASSIGNMENT HISTORY**Assignee**

GLAXOSMITHKLINE BIOLOGICALS S.A.
RUE DE L' INSTITUT 89 RIXENSART, B-1330

Assignor

NOVARTIS AG

Recorded: July 14, 2015

Assigned: July 13, 2015

Reel/Frame: 5578/0546

Action: NUNC PRO TUNC ASSIGNMENT EFFECTIVE 03/02/2015

Assignee

GLAXOSMITHKLINE BIOLOGICALS S.A.
RUE DE L'INSTITUT 89 1330 RIXENSART

Assignor

NOVARTIS AG

Recorded: May 27, 2015

Assigned: March 2, 2015

Reel/Frame: 5526/0001

Action: ASSIGNS THE ENTIRE INTEREST AND GOODWILL

© 2016 Corsearch

INTELLECTUAL PROPERTY LAW

Date Generated : July 25, 2016

FILE RECORD

IXIAROUS Federal
of 1

Status: Registered

Affidavit(s): 8 & 15, September 01, 2015

Last Status Received: Registered 8 & 15, September 1,
2015

Most Recent Owner:

Glaxosmithkline Biologicals S.A. (Belgium Corp.)

Goods/Services:

Int'l Class(es): 5 (U.S. Class: 6, 18, 44, 46, 51, 52)

Vaccines for human use

APPLICATION / REGISTRATION INFO.

Registration No.: 3660894

Registered: July 28, 2009

Serial No.: 77-661317

Filed: February 2, 2009

Published: May 12, 2009

Trademark Type: Word

Publications:

2009-20

Section: Publication Date of Application

Published: May 12, 2009

Type: Originally filed based on section 44(e)

Register Type: Principal Register

ADDITIONAL INFO.

Correspondence Address:

ANGELA L. WILSON GLAXOSMITHKLINE
LEGAL GLOBAL TRADEMARKS, MAILSTOP: 5.5A FIVE MOORE
DRIVE; RESEARCH TRIANGLE PARK NC 27709-0183

International Information

Foreign Designations:

Foreign: Switzerland

Registration No.: 501311

Registered: July 23, 2002

Expiration: July 11, 2012

Events:

September 1, 2015 - NOTICE OF ACCEPTANCE OF SEC. 8 & 15 -
E-MAILEDSeptember 1, 2015 - Registered - Sec.8 (6-Yr) Accepted & Sec.15
ACK.September 1, 2015 - CASE ASSIGNED TO POST REGISTRATION
PARALEGALAugust 26, 2015 - ASSIGNMENT OF OWNERSHIP NOT UPDATED
AUTOMATICALLY

July 31, 2015 - TEAS Section 8 & 15 Received

July 22, 2015 - AUTOMATIC UPDATE OF ASSIGNMENT OF
OWNERSHIP

June 6, 2015 - TEAS Change of Correspondence Received

June 3, 2015 - AUTOMATIC UPDATE OF ASSIGNMENT OF

OWNERSHIP

June 2, 2015 - Attorney Revoked And/Or Appointed
 June 2, 2015 - TEAS Revoke/Appoint Attorney Received
 October 22, 2009 - Certificate of Correction Issued
 October 22, 2009 - CASE ASSIGNED TO POST REGISTRATION
PARALEGAL
 September 4, 2009 - TEAS SECTION 7 REQUEST RECEIVED
 July 28, 2009 - Registered-Principal Register
 May 12, 2009 - Published For Opposition
 April 22, 2009 - Notice of Publication
 April 3, 2009 - Law office Publication Review Completed
 April 3, 2009 - Assigned to LIE
 April 3, 2009 - Approved for Pub - Principal Register
 April 2, 2009 - Assigned to Examiner
 February 5, 2009 - NEW APPLICATION OFFICE SUPPLIED DATA
 ENTERED IN TRAM
 February 5, 2009 - New Application Entered in Tram
TradeMark status details: REGISTERED 8 & 15
Other registration numbers: 2,775,583, 3,168,727
AM: CORRECTED NOVEMBER 24, 2009 - FOREIGN REG.
 EXPIRATION DATE

OWNER INFORMATION**2nd New Owner After Registration:**

GLAXOSMITHKLINE BIOLOGICALS S.A. (BELGIUM CORP.)
 RUE DE L' INSTITUT 89 RIXENSART, B-1330
 Belgium

1st New Owner After Registration:

GLAXOSMITHKLINE BIOLOGICALS S.A. (BELGIUM CORP.)
 RUE DE L'LNSTITUT 89 1330 RIXENSART
 Belgium

Registrant:

NOVARTIS AG (SWITZERLAND CORP.)
 CH-4002 BASEL
 Switzerland

Owner At Publication:

NOVARTIS AG (SWITZERLAND CORP.)
 CH-4002 BASEL
 Switzerland

Applicant:

NOVARTIS AG (SWITZERLAND CORP.)
 CH-4002 BASEL
 Switzerland

ASSIGNMENT HISTORY**Assignee**

GLAXOSMITHKLINE BIOLOGICALS S.A.
 RUE DE L' INSTITUT 89 RIXENSART, B-1330

Assignor

NOVARTIS AG

Recorded: July 14, 2015

Assigned: July 13, 2015

Reel/Frame: 5578/0546

Action: NUNC PRO TUNC ASSIGNMENT EFFECTIVE 03/02/2015

Assignee

GLAXOSMITHKLINE BIOLOGICALS S.A.
 RUE DE L'LNSTITUT 89 1330 RIXENSART

INTELLECTUAL PROPERTY LAW

Date Generated : July 25, 2016

FULL RECORD

US Federal
of 1**IXIARO**

Status: Registered

Affidavit(s): 8 & 15, September 25, 2012

Last Status Received: Registered 8 & 15, September 25, 2012

Most Recent Owner:

Glaxosmithkline Biologicals S.A. (Belgium Corp.)

Goods/Services:

Int'l Class(es): 5 (U.S. Class: 6, 18, 44, 46, 51, 52)

[pharmaceutical preparations for the treatment of and/or prevention of disorders of the nervous system, the immune system, the cardio-vascular system including diabetes and metabolic diseases, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, in oncology, in hematology, in transplantation, in ophthalmology, for use in the gastroenterological area and the prevention and treatment of ocular disorders or diseases; pharmaceutical preparations treating bacteria-based diseases; anti-infectives; anti-bacterials; antivirals; anti-biotics; anti-fungals;] vaccines [; diagnostic preparations for medical use]

APPLICATION / REGISTRATION INFO.

Registration No.: 3168727

Registered: November 7, 2006

Serial No.: 78-798170

Filed: January 24, 2006

Published: August 22, 2006

Trademark Type: Word

Publications:

2006-34

Section: Publication Date of Application

Published: August 22, 2006

Type: Originally filed based on section 44(e)

Register Type: Principal Register

ADDITIONAL INFO.

Correspondence Address:

ANGELA L. WILSON GLAXOSMITHKLINE
LEGAL GLOBAL TRADEMARKS, MAILSTOP: 5.5A FIVE MOORE
DRIVE; RESEARCH TRIANGLE PARK NC 27709-0183

International Information

Foreign Designations:

Foreign: Switzerland

Registration No.: 501311

Registered: July 11, 2002

Expiration: July 11, 2012

Events:

November 7, 2015 - COURTESY REMINDER - SEC. 8 (10-
YR)/SEC. 9 E-MAILED

August 26, 2015 - ASSIGNMENT OF OWNERSHIP NOT UPDATED
AUTOMATICALLY

July 22, 2015 - AUTOMATIC UPDATE OF ASSIGNMENT OF
OWNERSHIP

June 8, 2015 - TEAS Change of Correspondence Received

June 3, 2015 - AUTOMATIC UPDATE OF ASSIGNMENT OF

OWNERSHIP

June 2, 2015 - Attorney Revoked And/Or Appointed
 June 2, 2015 - TEAS Revoke/Appoint Attorney Received
 November 15, 2014 - SEC. 15 ACKNOWLEDGEMENT - MAILED
 November 15, 2014 - Registered - Sec. 15 Acknowledged
 November 14, 2014 - CASE ASSIGNED TO POST REGISTRATION
PARALEGAL
 November 13, 2014 - TEAS Section 15 Received
 September 25, 2012 - NOTICE OF ACCEPTANCE OF SEC. 8 -
 MAILED
 September 25, 2012 - Registered - Sec. 8 (6-Yr) Accepted
 September 25, 2012 - CASE ASSIGNED TO POST REGISTRATION
PARALEGAL
 September 17, 2012 - TEAS Section 8 Received
 January 2, 2008 - Attorney Revoked And/Or Appointed
 January 2, 2008 - TEAS Revoke/Appoint Attorney Received
 November 7, 2006 - Registered-Principal Register
 August 22, 2006 - Published For Opposition
 August 2, 2006 - Notice of Publication
 July 2, 2006 - Law office Publication Review Completed
 July 2, 2006 - Assigned to LIE
 June 6, 2006 - Approved for Pub - Principal Register
 June 6, 2006 - Examiner's Amendent Entered
 June 6, 2006 - Examiner's Amendment E-Mailed
 June 6, 2006 - Examiners Amendment - Written
 June 6, 2006 - Restore to TEAS Plus
 May 23, 2006 - Non-Final Action E-Mailed
 May 23, 2006 - Non-Final Action Written
 May 23, 2006 - REMOVED FROM TEAS PLUS
 May 23, 2006 - Assigned to Examiner
 January 30, 2006 - New Application Entered In Tram
TradeMark status details: REGISTERED 8 & 15
Other registration numbers: 2,775,583

OWNER INFORMATION**2nd New Owner After Registration:**

GLAXOSMITHKLINE BIOLOGICALS S.A. (BELGIUM CORP.)
 RUE DE L' INSTITUT 89 RIXENSART, B-1330
 Belgium

1st New Owner After Registration:

GLAXOSMITHKLINE BIOLOGICALS S.A. (BELGIUM CORP.)
 RUE DE L'INSTITUT 89 1330 RIXENSART
 Belgium

Registrant:

NOVARTIS AG (SWITZERLAND CORP.)
 CH-4002 BASEL
 Switzerland

Owner At Publication:

NOVARTIS AG (SWITZERLAND CORP.)
 4002 BASEL
 Switzerland

Applicant:

NOVARTIS AG (SWITZERLAND CORP.)
 4002 BASEL
 Switzerland

ASSIGNMENT HISTORY**Assignee**

GLAXOSMITHKLINE BIOLOGICALS S.A.